Loading stock data…
ONCO
$0.65+0.01 (+1.87%)
After Hours$0.62-0.03 (-4.16%)· Last close May 4
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Onconetix, Inc. in the Healthcare sector is trading at $0.65. The stock is currently near its 52-week low of $0.57, remaining 93.6% below its 200-day moving average. Technical signals show neutral RSI of 33 and bullish MACD crossover, explaining why ONCO maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 33) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.65
Potential Upside
5%
Whystock Fair Value$0.68
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vit...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$521,651
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.63
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-89.00%
Volume
Today's trading volume
593,898
Recent News
BC-Most Active Stocks
Megan Holdings Ltd. 7,893,938 0.2401
Realbotix Announces the Sale of Realbotix, LLC Subsidiary to Onconetix
Realbotix (XBOT.V) on Thursday said it entered into a definitive agreement with Onconetix, Inc (NASD
Onconetix announces financing through private placement, debt settlement
Onconetix (ONCO) announced the September 22, 2025 signing and closing of a private placement of shares of the Company’s Series D Convertible Preferred Stock, $0.00001 par value, and warrants to purchase up to an aggregate of 4,362,827 shares of the Company’s common stock, $0.00001 par value per share, for an aggregate purchase price of approximately $12.9 million. Approximately $9.3 million was paid in cash and the balance was used to offset certain amounts owed by the Company to certain investo
Onconetix receives additional delisting notice from Nasdaq
Onconetix (ONCO) received a staff delisting letter from Nasdaq on May 20 indicating that the company’s failure to file its Quarterly Report Q for the three months ended March 31, 2025 is in violation of Nasdaq’s continued listing requirements. The company received a deficiency notice from Nasdaq that the company was not in compliance with Nasdaq’s Listing Rules as set forth in the Rule given the company’s failure to timely file its Annual Report on Form 10-K for FY24. The company received a Staf